Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy

Area of Science:

• Oncolytic virotherapy
• Synthetic biology
• Cancer immunotherapy

Background:

• Oncolytic virotherapy faces challenges in specificity and immune response induction.
• Understanding cancer cell population dynamics is crucial for effective viral therapy.
• Hepatocellular carcinoma (HCC) remains a significant therapeutic challenge.

Purpose of the Study:

• To engineer programmable synthetic gene circuits for controlled adenoviral replication and immune effector release in HCC cells.
• To evaluate the therapeutic efficacy of engineered oncolytic adenoviruses in preclinical models.
• To investigate the synergistic effects of combining tumor lysis with immunomodulator secretion.

Main Methods:

• Construction of programmable and modular synthetic gene circuits for adenoviruses.
• Utilizing multiple promoter and microRNA inputs for selective gene expression in HCC cells.
• In vivo experiments using immunocompetent mouse models and computational simulations.

Main Results:

• Replicable adenovirus demonstrated superior tumor-killing efficacy compared to non-replicable adenovirus.
• Combined tumor lysis and immunomodulator secretion synergistically enhanced local lymphocyte cytotoxicity and systemic vaccination.
• Computational models predicted greater therapeutic efficacy for oncolytic viruses encoding immunomodulators versus combination therapies.

Conclusions:

• Engineered oncolytic adenoviruses with synthetic gene circuits offer an effective strategy for cancer treatment.
• This approach enhances specificity and immune response, potentially leading to novel immunotherapies for various cancers.
• The findings support the development of advanced oncolytic viral therapies for improved patient outcomes.